公开(公告)号：EP4242203A1

公开(公告)日：2023-09-13

申请号：EP21889635.5

申请日：2021-11-05

申请人： Pelemed Co., Ltd.

发明人： KIM, Yong Chul ,  PARK, Sung Gyoo ,  SEO, Jiwon ,  KIM, Woo Chan ,  JUNG, Jae Hoon ,  CHO, Yuri ,  KIM, Yoon Jun

IPC分类号： C07D401/12 ,  A61K31/5377 ,  A61K31/506 ,  A61P31/20 ,  A61P31/14 ,  A61P31/18 ,  C07D239/48

摘要： The present invention relates to a series of novel phenylaminopyridine derivatives and a use thereof for inhibiting capsid assembly and for preventing or treating virus infectious diseases thereby.

公开(公告)号：EP4253385A1

公开(公告)日：2023-10-04

申请号：EP22854147.0

申请日：2022-12-23

申请人： Pelemed Co., Ltd.

发明人： JANG, Soo Yeon ,  KIM, Myung Jin ,  PARK, Jin Hee ,  LEE, So Deok ,  OH, Su Jin ,  LEE, Eun Ji ,  KIM, Yong Chul ,  KIM, Woo Chan ,  LEE, Je Heon

IPC分类号： C07D487/10 ,  A61K31/404 ,  A61K31/4995 ,  A61P35/02 ,  C07D403/14 ,  C07D487/08

摘要： The present invention relates to novel indirubin derivatives having heterobicyclic moieties, and use thereof as fms-like tyrosine kinase 3 (FLT3) and rearranged during transfection (RET) kinase inhibitors. The compound of the present invention effectively inhibits the activity of FLT3 and RET kinases, and thus may be useful for preventing or treating mutant FLT3 and mutant RET-related diseases, particularly acute myeloid leukemia.

公开(公告)号：EP3705474A1

公开(公告)日：2020-09-09

申请号：EP18873750.6

申请日：2018-10-30

申请人： Pelemed Co., Ltd.

发明人： KIM, Yong Chul ,  JEONG, Pyeong Hwa

IPC分类号： C07D209/40 ,  A61K31/404 ,  A61K31/496 ,  C07D209/34 ,  C07D403/14

摘要： The present invention relates to a pharmaceutical composition for preventing or treating acute myeloid leukemia or metastatic breast cancer, comprising, as an active ingredient, an indirubin derivative. When the compound of the present invention is used, it can effectively inhibit the activity of FLT3 kinase and can be usefully used to prevent or treat acute myeloid leukemia or metastatic breast cancer.